Korean Industry Bid For Stem Cell Study Simplification Rejected
This article was originally published in PharmAsia News
South Korea’s Ministry of Food and Drug Safety has rejected a biotechnology industry demand to simplify the process to collect information on the safety and efficacy of stem cell therapies during clinical usage. From July, stem cell therapy companies will be obliged to conduct complete surveys on all patients who receive the therapies.
You may also be interested in...
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.